Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Head & Neck 2Gastrointestinal 2Other 1Gynecologic 1Endocrine 1Breast 1

Conditions

Multiple Endocrine Neoplasia Type 1 96Pituitary Neoplasms 57Neuroendocrine Tumors 50Thyroid Cancer, Papillary 42Thyroid Neoplasms 16Obesity 15Pheochromocytoma 14Overweight 11Adrenal Gland Neoplasms 10Weight Loss 9Paraganglioma 9Carcinoma, Neuroendocrine 9Pancreatic Neoplasms 8Prostatic Neoplasms 7Motor Activity 7Insulinoma 7Gastrointestinal Neoplasms 7Brain Neoplasms 7Adrenocortical Adenoma 7Acquired Immunodeficiency Syndrome 7Neoplasm Metastasis 6Hyperaldosteronism 6Carcinoma, Medullary 6Stomach Neoplasms 5Osteoporosis 5Neoplasms 5Meningioma 5Liver Neoplasms 5Insulin Resistance 5HIV Infections 5

Interventions

ziprasidone 1Olanzapine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Hyperlipidemias × Endocrine × Clear all
NCT00910988 2018-07-18

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Washington University School of Medicine

Phase NA Completed
46 enrolled 38 charts
Endocrine

Hyperglycemia, Hyperlipidemias, Insulin Resistance, Multiple Endocrine Neoplasia Type 1, Sedentary Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡